OBJECTIVE: Psoriasis is a common disease with profound impact on many facets of life; there is physical impairment as well as reductions in quality of life defined by psychological, social, sexual and financial parameters. Work productivity, another important component of patients' overall well-being, has also been reported to be impacted by psoriasis. The objective of this study was to determine whether there exists a relationship between clinical severity of psoriasis and work productivity. METHODS: To quantify the impact of psoriasis on work productivity, 90 patients were surveyed in a clinic setting. Three severity groups were created based on Psoriasis Area and Severity Index (PASI) scores: mild <10, moderate = 10-20, and severe >20. Work impairment was measured using the Work Productivity Assessment Index (WPAI); physical and mental health statuses were assessed using the SF-8; Anxiety/Depression was assessed using the HADS; other health and employment information were also collected. RESULTS: One-third of all subjects were unemployed at the time of the study with 16.7% of these subjects (5.5% of all 90 subjects) reporting that they were unemployed because of their psoriasis. A greater percentage of patients in the moderate and severe groups attributed their unemployment to psoriasis (33% for each), compared with the mild group (9.5%). There was a trend toward increasing impairment while at work with increasing psoriasis severity (severe 24.4%, moderate 17.7% and mild 13.5%). With respect to the percent with activity impairment, there was a statistically significant difference between the severe group (42%) and the mild group (20.2%)[all p < 0.05]. CONCLUSIONS: Psoriasis is associated with work productivity impairment, and the degree of work impact, missed work, physical and mental health condition and anxiety/depression status tends to be greater in patients with more severe skin involvement. These findings support the need for aggressive but appropriate treatment of moderate-to-severe psoriasis. Up to now, there are few economic analyses which construct models taking account of tobacco-associated diseases in Japan.
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SMOKING PSM1 DEVELOPING MARKOV-MODEL INCLUDING TOBACCO-ASSOCIATED DISEASES TO EVALUATE SMOKING CESSATION THERAPY IN JAPAN
Igarashi A, Takuma H, Fukuda T, Tsutani K Tokyo University, Bunkyo, Tokyo, Japan Up to now, there are few economic analyses which construct models taking account of tobacco-associated diseases in Japan.
OBJECTIVES:
To develop Markov-model, including various tobacco-associated diseases to evaluate effects of nicotinereplacement therapy (NRT) and smoking cessation guidance therapy. METHODS: To identify various tobacco-associated diseases and markov transition probabilities, we organized a committee including expert physicians. With expert interview, we developed a Markov-model. RESULTS: We identified 19 tobacco-associated diseases as major results of smoking, accord-ing to "Health Risk Appraisal". The 19 diseases are as follows; 10 cancers-oropharyngeal cancer, esophageal cancer, gastric cancer, hepatic cancer, rectal cancer, pancreatic cancer, lung cancer, cervical cancer, renal cancer and bladder cancer; 4 cardiovascular diseases-hypertensive heart disease, ischemic heart disease, aneurysm and apoplexy; and 5 other diseasespneumonia, chronic bronchitis, asthma, gastric ulcer and cirrhosis. Tobacco is thought to increase incidence rate of those 19 diseases. We constructed four node Markov model, "Success (of smoking cessation)" "Failure" "Death" and "Sick". "Sick" node consists of 19 diseases. We also considered a combination of major diseases. In order to avoid many branches, we settled the transition probabilities of diseases as a cumulative function of incidence of each disease. The main assumptions are as follows; 1) Only one disease occurs during each cycle; 2) The risk of each disease increases as cumulative tobacco consumption increases; and 3) Smoking affects the incidence rate of the 19 diseases but does not affect mortality rate from those diseases. One cycle in Markov chain is set to 5 year. For future cost-effectiveness analysis of smoking cessation therapy, we set cost as well as transition probability on each branch. CONCLUSIONS: We developed Markov-model, including various tobacco-associated disease. In the future, we will take cost-effectiveness analysis to evaluate smoking cessation therapy using this model.
PSM2 CONFIRMATORY FACTOR ANALYSIS AND RELIABILITY OF THE "SMOKING EFFECTS INVENTORY"
Cappelleri JC 1 , Bushmakin AG 1 , Baker CL 2 , Merikle E 3 , Olufade AO 2 , Gilbert DG 4 1 Pfizer Global Research and Development, Groton, CT, USA; 2 Pfizer Global Pharmaceuticals, New York, NY, USA; 3 Pfizer Canada, Montreal, QC, Canada; 4 Southern Illinois University, Carbondale, IL, USA OBJECTIVES: The "Smoking Effects Inventory" (SEI) assesses the degree to which subjects experience both desirable and aversive effects from smoking. To date, no formal psychometric analyses of the SEI have been published. We therefore tested the validity and reliability of the pre-specified grouping of items on the SEI. METHODS: Data came from three Phase II clinical trials (n = 626, n = 627, n = 312) of varenicline, developed for smoking cessation, using an adapted version of the SEI with 12 items (one item on enjoying smoking was added). Each item was scored on a seven-point scale (one = "Not at all" to seven = "Extremely") in response to the experience of the reinforcing effects of smoking. The pre-specified domains and single-item scales were Satisfaction (satisfaction, good taste, enjoying smoking); Psychological Reward (calming, feeling awake, reducing irritability, helping concentration, reducing hunger); Aversion (dizziness, nausea); Enjoyment of Respiratory Tract Sensations; and Craving Reduction. Confirmatory factor analyses and internal consistency reliability analyses (Cronbach's alpha) on multiitem domains were performed at baseline in each of the three trials. RESULTS: The postulated multidimensional framework of the SEI was supported by confirmatory factor analysis in each of the three studies. Comparative fit indexes (CFI) and non-normed fit indexes (NNFI) in the three trials exceeded 0.90 (CF = 0.94, 0.95, 0.94; NNFI = 0.92, 0.93, 0.92). Cronbach's alpha exceeded 0.80 in the three studies for the Satisfaction domain (Cronbach's alpha: 0.82, 0.85, 0.84) and the Psychological Reward domain (0.84, 0.82, 0.83) but was less than 0.60 for the Aversion domain (0.50, 0.55, and 0.56). CONCLUSION: The validity of the postulated multidimensional framework of the SEI is confirmed and supported by the data. Although reliability (internal consistency) of the Aversion domain was not high, excellent reliability was evident on the Satisfaction domain and the Psychological Reward domain.
PSM3 CONFIRMATORY VALIDATION OF THE BRIEF QUESTIONNAIRE OF SMOKING URGES
Cappelleri JC 1 , Bushmakin AG 1 , Baker CL 2 , Merikle E 3 , Olufade AO 2 , Gilbert DG 4 1 Pfizer Global Research and Development, Groton, CT, USA; 2 Pfizer Global Pharmaceuticals, New York, NY, USA; 3 Pfizer Canada, Montreal, QC, Canada; 4 Southern Illinois University, Carbondale, IL, USA OBJECTIVES: The 10-item version of the 32-item Questionnaire of Smoking Urges (the QSU-brief) provides a multidimensional measure of craving to smoke. Previous research from a factor analysis of the QSU-brief supported a two-factor structure with Factor 1 measuring "a strong desire and intention to smoke with smoking perceived as rewarding" and Factor 2 measuring "demonstrating anticipation of relief from negative affect and an urgent desire to smoke". We conducted an independent investigation of the QSU-brief to assess the validity and reliability of the proposed two-factor structure. METHODS: Data came from a seven-week Phase II clinical trial (n = 626) of varenicline developed for smoking cessation. The two pre-specified domains from previous research were Factor 1 (5 items) and Factor 2 (3 items). Factor analyses and internal consistency reliability analyses (Cronbach's alpha) were conducted during occasions when varying levels of craving intensity might be expected (baseline, Week 2, and Week 4). RESULTS: The hypothesized multidimensional framework of the QSU-brief was supported by confirmatory factor analysis at each of the three occasions (baseline, Week 2, Week 4). Comparative fit indexes (CFI) and non-normed fit indexes (NNFI) exceeded 0.90 (CFI = 0.97, 0.95, 0.96; NNFI = 0.96, 0.93, 0.95). Values of Cronbach's alpha exceeded 0.75 on Factor 1 (0.90, 0.89, 0.90) and Factor 2 (0.76, 0.78, 0.85), as well as on the Total Score of 10 items (0.92, 0.93, 0.93). CONCLUSION: The validity and reliability of the postulated two dimensional structure of self-reported craving as measured by the QSU-brief is confirmed.
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COST-EFFECTIVENESS OF CLOPIDOGREL VERSUS ASPIRIN IN THE PREVENTION OF ISCHEMIC EVENTS IN STROKE AND TIA PATIENTS: A FOUR-EUROPEAN COUNTRY ANALYSIS
Palmer AJ 1 , Roze S 1 , Hankey G 2 , Hakimi Z 3 , Spiesser J 3 , Carita P 3 , Gabriel S 3 1 CORE-Center for Outcomes Research, Binningen, Basel, Switzerland; 2 Royal Perth Hospital, Perth, Australia; 3 Sanofi-Aventis, Bagneux, France OBJECTIVES: To assess the cost-effectiveness of 18-month treatment with clopidogrel versus aspirin in high-risk patients with a recent history of Ischemic Stroke (IS) or Transient Ischemic Attack (TIA) in four European countries: Belgium, France, Switzerland, and UK. METHODS: We developed a Markov model based on patients with IS or TIA in the previous 90 days (median 15 days) who were treated with clopidogrel in the MATCH trial and followed prospectively for the occurrence of recurrent IS or TIA, myocardial infarction (MI), other cardiovascular death, life threatening bleeding, or major bleeding. The event rates for IS and TIA patients treated with aspirin were derived from a Cochrane review comparing clopidogrel and aspirin by using a relative risk increase (RRI) of 1.11 for serious vascular events (all strokes, MI, cardiovascular deaths). For major bleedings with aspirin vs. clopidogrel, we used a RRI of 1.12 (CAPRIE trial). Death rates for other causes were country specific and adjusted for this population. Lifetime perspective was chosen and discount rates were applied according to the local guidelines. RESULTS: Eighteen-month treatment with clopidogrel compared to aspirin was associated with a gain in quality adjusted life years (QALY) ranging from 31 years/1000 patients in the UK to 36 years/1000 patients in Belgium. The incremental cost per patient varied from 487€ in UK to 724€ in Belgium and the cost per QALY was 20,111€ in Belgium, 18, 882€ in France, 15, 620€ in Switzerland, and 15, 713€ in UK. Sensitivity analyses showed that all results were robust under various assumptions. CONCLUSION: Consistent results are found across the four countries with incremental costeffectiveness ratio below the acceptable thresholds, demonstrating that clopidogrel compared to aspirin is always cost-effective in the studied population.
